Huakang Zhou said in an interview in August that he was under SEC investigation, though the current status of it isn't clear. He declined to comment on Wednesday.
周华康今年8月在接受采访时曾说,他在接受SEC的调查。不过此项调查目前的进展情况尚不清楚。周华康周三拒绝发表评论。
Mr. Siris is another gatekeeper -- he was a paid consultant to China Yingxia and other Chinese companies he invested in, the SEC said in court documents.
赛瑞斯是另一位“看门人,SEC在一份法庭文件中说,他接受报酬担任了中国英霞他其他一些他所投资中资公司的顾问。
He also has invested in other Chinese companies that have faced criticism, such as China Sky One Medical Inc., which the SEC charged in September with falsely inflating its earnings. The company couldn't be reached for comment.
赛瑞斯在其他一些受到指责的中资公司也有投资,天一药业(China Sky One Medical Inc.)就是其中一家,SEC今年9月指控天一药业虚报公司收益。记者无法联系到这家公司置评。
【中概股“看门人”受调查】相关文章:
★ 清明节双语介绍
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15